Mental health changes after 4 months of weight loss treatment with the glucagon‐like peptide‐1 analogue liraglutide 3.0 mg
Authors' conclusion
Liraglutide treatment was associated with weight loss without adverse mental health changes. Mental health benefits may be seen especially in those initially impaired. Weight loss was irrespective of baseline mental health status, suggesting liraglutide weight loss treatment effectiveness even in the presence of impaired mental health.
Study context
- Population
- Patients with obesity treated with liraglutide 3.0 mg
- Participants
- 98 patients
- Exposure
- Liraglutide 3.0 mg, baseline vs 4-month follow-up
- Liraglutide 3.0 mgn = 98
- Outcome
- Changes in mental health and wellbeing (HADS total 0-42, depression/anxiety subscales 0-21; OBESI-Q psychological wellbeing 0-100)
- Follow-up
- 4 months
Main finding
As reported in the abstract
HADS total score change
−1.7
95% CI −3.2; −0.1p < 0.05
HADS depression score change
−1.0
95% CI −1.9; −0.1p < 0.05
HADS anxiety score change (in trend)
−0.7
95% CI −1.5; 0.1p = 0.095
OBESI-Q psychological wellbeing score change
4.3
95% CI 0.8; 7.8p < 0.05
Observational data: associations, not effects.
Further findings
Body weight change · 4 months
- Body weight change
- −5.8%, p < 0.001
Subgroups by baseline mental health · 4 months
- Mental health improvements occurred mainly in patients with poor baseline mental health
- Weight loss occurred regardless of initial mental health
Association of anthropometric changes with mental health
- Anthropometrics changes were associated with changes in mental health and psychological wellbeing either significantly or in trend
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →